Amazon is diving further into decentralised clinical trials.
Amazon Web Services (AWS) and decentralised clinical trial (DCT) technology and consultancy provider THREAD today announced they are collaborating to launch enhancements to the latter’s artificial intelligence-driven platform.
The newly added automation into THREAD’s DCT platform is designed to accelerate initiation of co-created and configured trials by reducing the start-up time to onboard users of the platform by as much as 30%. Also, users would be able to eliminate inefficiencies by more than 30% and reach as much as 25% cost savings when precompleting data. This reduces data capture and removing source data verification.
Further, users can precisely monitor and support investigation success by having richer data in real time, including real-time grades on trial performance. It also allows a secure review of participant data across the study, artificial intelligence support, and operational controls.
THREAD CEO John Reites said: “We are further scaling our DCT platform with next-level automation, AI/ML offerings, and optimised features focused to meet the evolving needs of our customers, research sites, and participants.”
AWS healthcare and life sciences general manager Dan Sheeran added: “The breadth and depth of AWS’s machine learning and cloud capabilities will help support THREAD teams as they work to automate processes, reduce inefficiencies, and monitor and support clinical trials.”
Amazon subsidiary AWS offers cloud computing platforms and application programming interface on a pay-as-you-go basis. Through the years, THREAD has been engaging with many players in the AI and clinical trials sector to bolster its capabilities.
Here at Clinical Trials Arena, we have been closely following the increasing uptake of DCTs, from pinpointing who and what is at the crest of the DCT wave, to the details such as challenges in direct-to-patient remote drug delivery and issues surrounding remote clinical trial monitoring.